Rocket Pharmaceuticals, INC Form 4 insider transactions

John Militello, Vice President of Finance, Treasurer, and Principal Accounting Officer of Rocket Pharmaceuticals, sold 1,064 shares of common stock to cover tax withholding obligations related to vesting RSUs.

Kinnari Patel, President, Head of R&D and Chief Operating Officer of Rocket Pharmaceuticals, sold 3,989 shares of common stock on August 16, 2024, to cover tax withholding obligations related to vesting RSUs.

Gaurav Shah, CEO of Rocket Pharmaceuticals, sold 9,650 shares of common stock on August 16, 2024, to cover tax withholding obligations related to vesting RSUs.

Martin Wilson, General Counsel of Rocket Pharmaceuticals, sold 1,027 shares of common stock on August 16, 2024, to cover tax withholding obligations related to vesting RSUs.

John Militello, a Vice President at Rocket Pharmaceuticals, sold 812 shares of common stock on July 22, 2024, to cover tax withholding obligations related to vesting RSUs.

Mark Andrew White, a General Manager at Rocket Pharmaceuticals, sold 3,026 shares of common stock at a price of $20.395 on July 8, 2024.

Director Roderick Wong acquired stock options for Rocket Pharmaceuticals shares on June 13, 2024.

Director David P. Southwell reports the acquisition of stock options for 23,944 shares of Rocket Pharmaceuticals' common stock.

Director Elisabeth Bjork acquired stock options for Rocket Pharmaceuticals shares on June 13, 2024.

Director Naveen Yalamanchi acquired stock options for 23,944 shares of Rocket Pharmaceuticals common stock on June 13, 2024.

Director Keith Woods acquired options to purchase 23,944 shares of Rocket Pharmaceuticals stock on June 13, 2024.

Fady Ibraham Malik, a director of Rocket Pharmaceuticals, acquired options to purchase 23,944 shares of common stock on June 13, 2024.

Director Gotham Makker acquired stock options in Rocket Pharmaceuticals, exercisable for 26,604 shares of common stock.

Director Pedro Granadillo acquired stock options for Rocket Pharmaceuticals shares, vesting in June 2025.

Carsten Boess, a director of Rocket Pharmaceuticals, acquired stock options for 23,944 shares of common stock on June 13, 2024.

Gotham Makker, a director of Rocket Pharmaceuticals, amended a previous SEC Form 4 filing to accurately reflect beneficial ownership of common stock, including shares held by a non-revocable trust.

Director David P. Southwell transferred shares of Rocket Pharmaceuticals common stock to an irrevocable trust on May 2, 2024.

John Militello, a Vice President at Rocket Pharmaceuticals, sold 1,079 shares of common stock to cover tax withholding obligations related to the vesting of Restricted Stock Units (RSUs).

CEO Gaurav Shah of Rocket Pharmaceuticals reports acquisition and disposal of common stock and restricted stock units (RSUs).

Martin Wilson, General Counsel of Rocket Pharmaceuticals, reports the acquisition and disposal of common stock and restricted stock units (RSUs).

Kinnari Patel, a Rocket Pharmaceuticals executive, reports the acquisition and disposal of common stock and restricted stock units.

John Militello, Vice President of Finance, Treasurer, and Principal Accounting Officer of Rocket Pharmaceuticals, sold 833 shares of common stock on April 22, 2024, to cover tax withholding obligations related to vesting RSUs.

Director David Southwell exercised stock options and sold shares of Rocket Pharmaceuticals (RCKT) to cover tax obligations.

Mark Andrew White, a General Manager at Rocket Pharmaceuticals, sold 12,532 shares of common stock on April 8, 2024, at a price of $24.638 per share.

Chief Financial Officer of Rocket Pharmaceuticals, Aaron Ondrey, reports the acquisition of restricted stock units and stock options.

Director Gotham Makker sold 274,000 shares of Rocket Pharmaceuticals (RCKT) at a price of $28.4341 on March 21, 2024.

John Militello, VP, Principal Accounting Officer, and Interim Principal Financial Officer of Rocket Pharmaceuticals, sold 2,490 shares of common stock on March 21, 2024, to cover tax obligations related to RSU vesting.

John Militello, VP and Principal Accounting Officer of Rocket Pharmaceuticals, exercised stock options and sold 10,000 shares of common stock on February 29, 2024.

Martin Wilson, General Counsel of Rocket Pharmaceuticals, sold 4,100 shares of common stock on February 29, 2024, at an average price of $29.331 per share.